访问教授
所在学院 免疫化学研究所
研究方向 癌症和传染性疾病的生物技术药物
联系方式 hongkaizhang@126.com zhanghk@shanghaitech.edu.cn
教育经历
2000/09—2004/07，南开大学，学士
2004/09—2009/07，南开大学，博士
工作经历
2009/10—2013/09，Scripps Research Richard Lerner课题组，博士后
2013/10—2016/04，Scripps Research Richard Lerner课题组，Senior Scientist
2016/05—至今，南开大学，研究员
2019/12—至今，上海科技大学免疫化学研究所，访问教授
研究内容
围绕癌症和传染性疾病开发生物技术药物并基于耐药机制和转化医学研究发展药物联用策略。
1、肿瘤免疫抗体开发及其耐药机制研究
2、溶瘤病毒药物开发及其耐药机制研究
3、肿瘤免疫细胞治疗开发及其耐药机制研究
4、传染性疾病的中和性抗体及多特异性抗体开发
代表性论文
1. Kai Ye, Fan Li, Ruikun Wang, Tianyi Cen, Shiyu Liu, Zhuoqian Zhao,Ruonan Li, Lili Xu, Guanmeng Zhang, Zhaoyuan Xu, Li Deng,Lili Li,Wei Wang, Alexey Stepanov, Yajuan Wan,Yu Guo, Yuanke Li,Yuan Wang,Yujie Tian, Alexander G. Gabibov, Yingbin Yan*, Hongkai Zhang*. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ. Molecular Therapy. 2022.S1525-0016(22)00370-7.
2.Yuexia Liang#, Xin Li#, Fengping Peng, Xiaohan Ye,Wei Wang, Tianyi Cen, Fan Li,Yue Lu, Zhaoyun Liu, Hui Liu, Kai Ding, Kai Ye, Yang Yu, Tianyu Ma, Sihe Zhang, Yi Huang, Yuan Wang, Xue Yang, Rong Fu*, Hongkai Zhang*. Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing. Theranostics 2022. 12(18):7729-7744.
3.Xin Jin#, Meng Zhang#, Rui Sun#, Hairong Lyu, Xia Xiao , Xiaomei Zhang, Fan Li, Danni Xie , Xia Xiong , Jiaxi Wang , Wenyi Lu*, Hongkai Zhang*，Mingfeng Zhao*, First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. Journal of Hematology & Oncology. 2022.15(1):88.
4.Yuan Wang#, Ruina Jin#, Bingqing Shen, Na Li, He Zhou, Wei Wang, Yingjie Zhao, Mengshi Huang, Pan Fang, Shanshan Wang, Pascaline Mary, Ruikun Wang, Peixiang Ma, Ruonan Li, Yujie Tian, Youjia Cao, Fubin Li, Liang Schweizer, Hongkai Zhang*. High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics. Science Advances. 2021.7(24):eabe3839.
5.Yu Guo*#,Lisu Huang#, Guangshun Zhang#, Yanfeng Yao#, He Zhou#, Shu Shen# ,Bingqing Shen, Bo Li, Xin Li, Qian Zhang, Mingjie Chen, Da Chen, Jia Wu, Dan Fu, Xinxin Zeng,Mingfang Feng, Chunjiang Pi, Yuan Wang, Xingdong Zhou , Minmin Lu, Yarong Li, Yaohui Fang,Yun-Yueh Lu, Xue Hu, Shanshan Wang, Wanju Zhang, Ge Gao, Francisco Adrian, Qisheng Wang ,Feng Yu, Yun Peng, Alexander G. Gabibov, Juan Min, Yuhui Wang, Heyu Huang, Alexey Stepanov,Wei Zhang , Yan Cai, Junwei Liu, Zhiming Yuan, Chen Zhang, Zhiyong Lou*, Fei Deng*,Hongkai Zhang*, Chao Shan*, Liang Schweizer*, Kun Sun*, Zihe Rao*, A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nature Communications. 2021.12(1):2623.
